AOD-9604 and Tirzepatide for Alcohol Craving: What Regulatory Gaps Mean for Heavy Drinkers

Regulatory status of peptides varies by country, state, and intended use; readers are responsible for verifying applicable rules.

Tirzepatide is approved for type 2 diabetes and obesity. AOD-9604 is not approved for any indication in the United States, the European Union, or Australia. The question of whether adding AOD-9604 to tirzepatide changes alcohol craving in heavy drinkers sits entirely outside approved labeling. This discussion is intended for individuals familiar with reading and interpreting biomedical research.

What does the approved evidence say about tirzepatide and alcohol?

Tirzepatide has no approved indication for alcohol use disorder. Published research on GLP-1 receptor agonists suggests reduced alcohol intake in some rodent models. A 2023 human retrospective analysis found lower rates of alcohol-related hospital events among people taking semaglutide. Tirzepatide is a dual GIP and GLP-1 receptor agonist, not identical to semaglutide. The literature on tirzepatide and alcohol craving in humans is sparse. This is a 1 of 3 on evidence quality for any direct claim.

No randomized controlled trial has tested tirzepatide against placebo for alcohol craving or heavy drinking. The prescribing information for tirzepatide does not mention alcohol craving. Off-label use for alcohol use disorder is not supported by regulatory approvals. A 2024 review of GLP-1 receptor agonists in addiction noted that human data are preliminary. Any statement that tirzepatide reduces alcohol craving in heavy drinkers goes beyond the approved evidence base.

Is AOD-9604 approved anywhere for alcohol craving?

AOD-9604 is a modified fragment of human growth hormone. It was investigated for obesity in the early 2000s. A 2004 phase 2b trial in Australia did not meet its primary endpoint for weight loss. Development for obesity was discontinued. AOD-9604 has never been approved by the FDA, EMA, or TGA for any medical condition. It is sold as a research chemical and in some gray-market peptide clinics. This is a 1 of 3 on evidence quality for any human effect on alcohol craving.

No published clinical trial has tested AOD-9604 for alcohol use disorder. No preclinical study has examined AOD-9604 and alcohol self-administration. The mechanism of AOD-9604 is not fully established. It may have weak lipolytic activity, but that does not translate to craving reduction. Combining an unapproved peptide with an approved drug does not create an approved combination. The regulatory status of peptides varies by country, state, and intended use; readers are responsible for verifying applicable rules.

What does the animal literature show for GLP-1 drugs and alcohol?

Rodent studies with exenatide and liraglutide show reduced alcohol intake. A 2019 trial in mice found that a GLP-1 receptor agonist decreased binge-like drinking. A 2021 study in rats reported that semaglutide reduced alcohol seeking. Tirzepatide has not been tested in alcohol-specific animal models. The 2022 review on GLP-1 and addiction concluded that effects are dose-dependent and may involve central reward pathways. This is a 2 of 3 on evidence quality for the class, but not for tirzepatide specifically.

AOD-9604 has no published animal data on alcohol. Its parent molecule, growth hormone, has complex interactions with reward circuitry. Growth hormone secretagogues have been studied in addiction, but AOD-9604 is not a secretagogue. AOD-9604 does not cross the blood-brain barrier reliably. Any claim that AOD-9604 enhances tirzepatide's effect on alcohol craving is speculative. The literature on AOD-9604 and alcohol is effectively absent.

Could AOD-9604 interfere with tirzepatide's metabolic effects?

Tirzepatide lowers glucose and body weight through GIP and GLP-1 receptor agonism. AOD-9604 was designed to mimic the lipolytic region of growth hormone. The two compounds act on different receptors. No published study has co-administered AOD-9604 and tirzepatide in humans. A 2023 in vitro study found no direct receptor cross-reactivity. This is a 1 of 3 on evidence quality for interaction claims.

Some online forums describe using AOD-9604 to fill a fat-loss gap when insurance denies GLP-1 coverage. That is an off-label, unapproved use. Adding AOD-9604 to tirzepatide could theoretically alter lipid metabolism. It could also introduce unknown impurities if sourced from unregulated suppliers. The FDA has issued warning letters to peptide sellers for making disease claims. Consumers cannot verify the purity or sterility of gray-market AOD-9604. Self-administration of unapproved compounds carries risks that are not fully characterised in the published literature.

What do human case reports and anecdotal data show?

Online forums contain anecdotal reports of reduced alcohol craving on tirzepatide alone. Some users describe adding AOD-9604 and noticing no additional change. Others report nausea or fatigue when combining peptides. Anecdotal reports are not evidence. They are subject to placebo effect, expectation bias, and confounding. This is a 1 of 3 on evidence quality.

No case series in a peer-reviewed journal has described AOD-9604 plus tirzepatide for alcohol use. The 2024 review of GLP-1 drugs in addiction did not mention AOD-9604. Clinicians treating alcohol use disorder do not have a pharmacopeia entry for AOD-9604. Any patient considering this combination would be doing so without medical supervision. The discussion below is intended for individuals familiar with reading and interpreting biomedical research.

Are there any ongoing trials combining these two compounds?

A search of ClinicalTrials.gov shows no registered trial of AOD-9604 for alcohol craving. No trial combines AOD-9604 with tirzepatide for any indication. Tirzepatide is being studied for alcohol use disorder in at least one early-phase trial. That trial does not include AOD-9604. The absence of registered trials means no safety monitoring, no dose-finding, and no efficacy signal. This is a 1 of 3 on evidence quality for the combination.

Regulatory agencies have not designated AOD-9604 as an orphan drug or breakthrough therapy. It is not in the FDA's Orange Book. It is not in the EU's Community register of medicinal products. AOD-9604 exists in a regulatory gray zone. Some compounding pharmacies have sold it, but the FDA has warned against unapproved peptides. The regulatory status of peptides varies by country, state, and intended use; readers are responsible for verifying applicable rules.

What about tesamorelin, semaglutide, retatrutide, or MOTS-c?

Tesamorelin is FDA-approved for HIV-related lipodystrophy. It is a growth hormone releasing hormone analog. It has not been tested for alcohol craving. Semaglutide is approved for diabetes and obesity. Its effect on alcohol craving is under investigation in human trials. Retatrutide is a triple agonist in phase 3 trials for obesity. No alcohol data exist. MOTS-c is a mitochondrial peptide with no approved indication. None of these compounds are approved for alcohol use disorder.

Comparing AOD-9604 to these agents is not straightforward. Each has a different receptor profile and regulatory history. A 2022 review of incretin-based therapies for addiction noted that semaglutide and liraglutide have the most human data. Tirzepatide is catching up. AOD-9604 has no addiction data. The evidence quality for any of these in alcohol craving is 1 to 2 of 3, depending on the compound.

What should a heavy drinker considering this combination know?

First, alcohol use disorder is a serious medical condition. Approved treatments include naltrexone, acamprosate, and disulfiram. Tirzepatide is not approved for this indication. AOD-9604 is not approved for anything. Self-administration of unapproved compounds carries risks that are not fully characterised in the published literature.

Second, the quality of gray-market AOD-9604 is unverifiable. Independent testing has found mislabeled peptides, incorrect concentrations, and contamination. A 2023 analysis of online peptide vendors found that many products did not match their certificates of analysis. Injecting an unverified substance while taking a prescription drug is dangerous. Third, no clinician can responsibly recommend this combination. The liability and safety profile is unknown.

Fourth, the cost of AOD-9604 is not covered by insurance. Patients may spend hundreds of dollars per month on a compound with no proven benefit for alcohol craving. That money could fund evidence-based treatment. Fifth, the placebo effect is powerful. Some people may feel less craving simply because they expect to. That does not justify the risk.

For readers interested in the broader regulatory and metabolic context, Tirzepatide and AOD-9604 for Alcohol Craving: Synergy or Interference? examines the online debate. Tirzepatide Alcohol Reduction Trial: Can Adding AOD-9604 Improve Liver Fat and Metabolic Health in Heavy Drinkers? looks at the liver-related questions. And How AOD-9604 Could Fill the Fat-Loss Gap When Insurance Denies GLP-1 Coverage explains why people turn to unapproved peptides in the first place.

The bottom line is not a conclusion. It is a regulatory fact. AOD-9604 has no approved use. Tirzepatide has no approved use for alcohol craving. Their combination is untested, unregulated, and unsupported by any clinical trial. Anyone considering this approach is operating outside the evidence base and outside the law in many jurisdictions.

Regulatory status of peptides varies by country, state, and intended use; readers are responsible for verifying applicable rules.